BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Glycotope Presents Approved GlycoExpress-Technology at BIO-Europe 2010


11/12/2010 10:41:38 AM

Berlin, Germany, November 12, 2010 / b3c newswire / - Glycotope GmbH, a leading glycobiology company, will present recent advances with its GlycoExpress™ technology of novel human cell lines during the upcoming BIO-Europe in Munich. With two of its glycooptimized antibodies produced by GlycoExpress™ and already undergoing clinical trials, four European regulatory authorities approved GlycoExpress™ for production of biotherapeutics. This strongly validates this innovative technology for future development and production of therapeutic proteins. The preclinically observed advantages of glycooptimized biotherapeutics are expected to result in a clear clinical superiority. All glycooptimized products are produced in Glycotope´s own GMP facility in Heidelberg (Glycotope Biotechnology GmbH).

About GlycoExpress™

GlycoExpress™ is based on a tool box of glycoengineered human cell lines for glycooptimization and high yield production of glycooptimized biotherapeutics, such as antibodies. The antibody’s fully human glycosylation is optimized to yield a largely improved anti-tumor ADCC activity, bioavailability and contains no non-human immunogenic carbohydrate structures and facilitates treatment of a highly increased number of patients. Glycooptimization with GlycoExpress™ is not limited to antibodies but suitable for the majority of therapeutically relevant proteins. The technology platform is available for cooperation partners via service & license agreements.

About Glycotope GmbH - www.glycotope.com

GLYCOTOPE, founded in 2001, focuses on the optimization and humanization of therapeutically relevant carbohydrate structures known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. GlycoExpress™, one of the company’s proprietary technologies, allows making existing and new biopharmaceutical drugs more effective and tolerable in the human body, which is of considerable medical as well as economic importance. Glycotope evolved into a leading integrated glycobiology company, covering all phases in drug development from lead discovery, preclinical development, GMP production down to the clinical development. Glycotope´s most advanced pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other already marketed therapeutic proteins.

Contact:

Glycotope GmbH Dr. Franzpeter Bracht Robert-Roessle-Str. 10 13125 BERLIN Germany

Tel.: +49-30-9489-2600 Fax: +49-30-9489-2609 Web: www.glycotope.com eMail: news@glycotope.com



Read at BioSpace.com

Glycotope
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES